Humoral Responses Elicited by Adenovirus Displaying Epitopes Are Induced Independently of the Infection Process and Shaped by the Toll-Like Receptor/MyD88 Pathway

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Feb 21

PMID 29459860

Citations 5

Authors

Aleksandra Anchim

Najat Raddi

Lena Zig

Patrick Perrieau

Ronan Le Goffic

Bernhard Ryffel

Karim Benihoud

Affiliations

Soon will be listed here.

Abstract

The use of serotype 5 adenovirus (Ad)-derived vectors in vaccination is confronted to preexisting anti-Ad immunity. Epitope display on Ad capsid is currently being investigated as an alternative approach of vaccination. The present study seeks to better understand virus- and host-related factors controlling the efficacy of this new vaccination approach. In contrast to an Ad vector expressing ovalbumin as a transgene, Ad displaying an ovalbumin-derived B-cell epitope inserted into the fiber protein was able to elicit antibody responses in both Ad-naive and Ad-immune mice. Moreover, introduction of a set of mutations abrogating Ad interaction with its receptors did not modify the virus capacity to elicit a humoral response against the inserted epitope while reducing its capacity to mount antibody responses against the transgene product. Taken as a whole these data indicate that the efficacy of Ad displaying epitopes requires neither Ad binding to its receptors nor the infection process. In addition, the use of genetically deficient mice demonstrated that both toll-like receptor (TLR)/MyD88 and RIG-I/mitochondrial antiviral-signaling (MAVS) innate immunity pathways were dispensable to mount anti-epitope antibody responses. However, they also revealed that TLR/MyD88 pathway but not RIG-I/MAVS pathway controls the nature of antibodies directed against the displayed epitope.

Citing Articles

From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children.

Root-Bernstein R Int J Mol Sci. 2023; 24(3).

PMID: 36769320 PMC: 9917907. DOI: 10.3390/ijms24033001.

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.

Chevillard C, Amen A, Besson S, Hannani D, Bally I, Dettling V Mol Ther. 2022; 30(5):1913-1925.

PMID: 35151843 PMC: 8828441. DOI: 10.1016/j.ymthe.2022.02.011.

Adenovirus vector-based vaccine for infectious diseases.

Sakurai F, Tachibana M, Mizuguchi H Drug Metab Pharmacokinet. 2022; 42:100432.

PMID: 34974335 PMC: 8585960. DOI: 10.1016/j.dmpk.2021.100432.

Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine.

Porto P, Anjos D, Dabilla N, da Fonseca S, Souza M Infect Genet Evol. 2020; 85:104489.

PMID: 32758675 PMC: 7833690. DOI: 10.1016/j.meegid.2020.104489.

Toll-like receptor 4 signalling regulates antibody response to adenoviral vector-based vaccines by imprinting germinal centre quality.

Li R, Liu J, Wu S, Zai X, Li Y, Yang Q Immunology. 2018; 155(2):251-262.

PMID: 29876918 PMC: 6142292. DOI: 10.1111/imm.12957.

References

Appledorn D, Patial S, McBride A, Godbehere S, van Rooijen N, Parameswaran N . Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol. 2008; 181(3):2134-44. DOI: 10.4049/jimmunol.181.3.2134. View

Crouzet J, Naudin L, Orsini C, Vigne E, Ferrero L, Le Roux A . Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci U S A. 1997; 94(4):1414-9. PMC: 19805. DOI: 10.1073/pnas.94.4.1414. View

Vigne E, Dedieu J, Brie A, Gillardeaux A, Briot D, Benihoud K . Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther. 2003; 10(2):153-62. DOI: 10.1038/sj.gt.3301845. View

Lasaro M, Ertl H . New insights on adenovirus as vaccine vectors. Mol Ther. 2009; 17(8):1333-9. PMC: 2835230. DOI: 10.1038/mt.2009.130. View

Hartman Z, Kiang A, Everett R, Serra D, Yang X, Clay T . Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol. 2006; 81(4):1796-812. PMC: 1797572. DOI: 10.1128/JVI.01936-06. View

Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P . Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther. 2008; 16(8):1474-80. DOI: 10.1038/mt.2008.132. View

Kang S, Yoo D, Kim M, Song J, Park M, O E . MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J Virol. 2011; 85(21):11391-400. PMC: 3194946. DOI: 10.1128/JVI.00080-11. View

Mizuguchi H, Koizumi N, Hosono T, Uchida E, Utoguchi N, Watanabe Y . CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 2002; 9(12):769-76. DOI: 10.1038/sj.gt.3301701. View

Yang R, Martinez Murillo F, Delannoy M, Blosser R, Yutzy 4th W, Uematsu S . B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol. 2005; 174(12):7912-9. DOI: 10.4049/jimmunol.174.12.7912. View

10.

Sun Q, Sun L, Liu H, Chen X, Seth R, Forman J . The specific and essential role of MAVS in antiviral innate immune responses. Immunity. 2006; 24(5):633-42. DOI: 10.1016/j.immuni.2006.04.004. View

11.

McConnell M, Danthinne X, Imperiale M . Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol. 2006; 80(11):5361-70. PMC: 1472126. DOI: 10.1128/JVI.00256-06. View

12.

Bradshaw A, Coughlan L, Miller A, Alba R, van Rooijen N, Nicklin S . Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release. 2012; 164(3):394-402. PMC: 3520007. DOI: 10.1016/j.jconrel.2012.05.025. View

13.

Yamaguchi T, Kawabata K, Koizumi N, Sakurai F, Nakashima K, Sakurai H . Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum Gene Ther. 2007; 18(8):753-62. DOI: 10.1089/hum.2007.016. View

14.

Rogers G, Suzuki M, Zolotukhin I, Markusic D, Morel L, Lee B . Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. J Innate Immun. 2015; 7(3):302-14. PMC: 4417066. DOI: 10.1159/000369273. View

15.

Minamitani T, Iwakiri D, Takada K . Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J Virol. 2011; 85(8):4035-40. PMC: 3126113. DOI: 10.1128/JVI.02160-10. View

16.

Parker A, Waddington S, Nicol C, Shayakhmetov D, Buckley S, Denby L . Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006; 108(8):2554-61. DOI: 10.1182/blood-2006-04-008532. View

17.

Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K . Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine. 2010; 29(7):1463-71. DOI: 10.1016/j.vaccine.2010.12.025. View

18.

Zhu J, Huang X, Yang Y . The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009; 119(8):2388-98. PMC: 2719948. DOI: 10.1172/JCI37607. View

19.

Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E . Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther. 2003; 8(3):485-94. DOI: 10.1016/s1525-0016(03)00182-5. View

20.

Benihoud K, Yeh P, Perricaudet M . Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999; 10(5):440-7. DOI: 10.1016/s0958-1669(99)00007-5. View